Parenteral Manual

Anifrolumab (NON-FORMULARY)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Saphnelo™
Classification: 
Type I Interferon (IFN) Receptor Antagonist
Original Date: 
October 2024
Indications: 
  • Active autoantibody positive systemic lupus erythematosus (SLE)
Reconstitution and Stability: 
  • Available as 150 mg/mL vials of 300 mg.
  • Store vials in original cartons at 2 – 8°C. Do not freeze.
  • Do not shake. Protect from light.
  • Dilute dose in NS to a concentration of 3 to 6 mg/mL.
  • All products are preservative-free and, therefore, are single-use vials.
  • Once diluted in 0.9% sodium chloride, the dose should be administered immediately. However, if necessary, prepared solutions can be stored for 24 hours at 2 – 8°C and 4 hours at ≤ 30°C.
  • Do not use if the solution has discoloration, opaque particles or any foreign material observed.
Compatibility: 
  • Solutions compatible: 0.9% Sodium Chloride
  • Additives/Above Cassette Compatible: Unknown
  • Y-Site compatibility: Unknown
  • Incompatible: DO NOT infuse with any other medication or solution
Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM NO
IV Direct NO
IV Intermittent Infusion

YES

Infusion time: 30 minutes, administer using 0.22-micron low protein being in-line filter and flush with 25 mL 0.9% NaCl at end of infusion.
IV Continuous Infusion NO

 

Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • 300 mg IV every 4 weeks
Potential hazards of parenteral administration: 
  • Monitor for hypersensitivity reactions, including infusion-related and anaphylactic reactions (hypotension, tachycardia, bradycardia, dyspnea, wheezing, angioedema, rash, nausea, vomiting, diaphoresis).
Notes: 
  • Immunization with live vaccines is not recommended while receiving anifrolumab. It is recommended that prior to starting therapy, vaccination of patient with all appropriate immunizations should be completed according to current immunization guidelines.
References: 
  • Saphnelo™ Product Monograph, AstraZeneca Canada, June 2024

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.